Sign inJoin waitlistJoin the waitlist

Abdullah Kutlar

Director, MCG Center for Blood Disorders · Medical College of Georgia

Credentials: · · ·

History

MCG Center for Blood Disorders · Medical College of Georgia
Present
Medical College of Georgia
Present

Hematology
1974–1975
Internal Medicine
1971–1974
Medical College of Georgia
1967–1971

Research

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
New England Journal of Medicine · 1998 · 1,411 citations
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
New England Journal of Medicine · 2017 · 702 citations
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment
JAMA · 2003 · 690 citations

VM
Virgil Mckie
15 papers
Kenneth Ataga
14 papers
Robert Adams
12 papers
Elliott Vichinsky
11 papers
JK
Julie Kanter
10 papers
Nirmish Shah
10 papers
Victor Gordeuk
9 papers
Steffen Meiler
8 papers
Jane Hankins
7 papers
Jeffrey Glassberg
7 papers
KM
Kathleen Mckie
7 papers
Martin Steinberg
7 papers

Grants

"REAL Answers" (Registry Expansion Analyses to Learn)
National Heart, Lung, and Blood Institute · U01
PI · $9.7M · Icahn School of Medicine at Mount Sinai
2023–2028
Deep South KUH Premier Research and Inter-Disciplinary Mentored Education (PRIME)
National Institute of Diabetes and Digestive and Kidney Diseases · U2C
PI · $2.3M · University of Alabama at Birmingham
2023–2028
Phase I Study of Panobinostat in Adults with Sickle Cell Disease: Novel Approach to Recruitment and Retention
National Heart, Lung, and Blood Institute · R33
Contact PI · $2.3M · Augusta University
2023–2027
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell Disease
National Heart, Lung, and Blood Institute · U01
Contact PI · $5M · Augusta University
2016–2024

Clinical trials

The Role of Endothelin-1 in Sickle Cell Disease
Principal investigator · Completed · Phase 1
Augusta University
2015–2019
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Principal investigator · Recruiting · Phase 1
Abdullah Kutlar
2010–2027
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Site PI · Recruiting · Phase 4
Novartis Pharmaceuticals
2021–2031